Attached files
file | filename |
---|---|
EX-23.1 - EX-23.1 - Eledon Pharmaceuticals, Inc. | d582012dex231.htm |
S-1 - S-1 - Eledon Pharmaceuticals, Inc. | d582012ds1.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 30, 2018 relating to the financial statements of Novus Therapeutics Inc. (the Company) for the year ended December 31, 2016, which report expresses an unqualified opinion and includes an explanatory paragraph regarding the Companys ability to continue as a going concern, appearing in the Companys Annual Report on Form 10-K for the year ended December 31, 2017. We also consent to the reference to us under the heading Experts in such Registration Statement.
/s/ Brightman Almagor Zohar & Co.
Brightman Almagor Zohar & Co.
Certified Public Accountants
Member of Deloitte Touche Tohmatsu Limited
Tel Aviv, Israel
July 31, 2018